Spruce Street Capital LP Purchases 542,911 Shares of Enanta Pharmaceuticals, Inc. $ENTA

Spruce Street Capital LP grew its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 139.3% during the 1st quarter, HoldingsChannel reports. The firm owned 932,598 shares of the biotechnology company’s stock after acquiring an additional 542,911 shares during the quarter. Enanta Pharmaceuticals comprises about 2.8% of Spruce Street Capital LP’s investment portfolio, making the stock its 13th biggest position. Spruce Street Capital LP’s holdings in Enanta Pharmaceuticals were worth $11,779,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of ENTA. Meeder Asset Management Inc. bought a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $32,000. Seven Fleet Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $36,000. Strs Ohio acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Enanta Pharmaceuticals by 333.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 2,758 shares in the last quarter. Finally, Quarry LP acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at $81,000. Institutional investors own 94.99% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.29.

Enanta Pharmaceuticals Trading Down 1.3%

ENTA opened at $12.78 on Friday. Enanta Pharmaceuticals, Inc. has a 1-year low of $6.45 and a 1-year high of $17.15. The stock has a market capitalization of $371.64 million, a PE ratio of -4.93 and a beta of 0.96. The firm has a 50-day moving average price of $13.20 and a two-hundred day moving average price of $13.44.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. The firm had revenue of $17.16 million during the quarter, compared to analysts’ expectations of $17.03 million. On average, research analysts predict that Enanta Pharmaceuticals, Inc. will post -1.79 EPS for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.